Literature DB >> 18461567

CE-LIF method for the separation of anthracyclines: application to protein binding analysis in plasma using ultrafiltration.

Gillian Whitaker1, Amy Lillquist, Stephanie A Pasas, Robert O'Connor, Fiona Regan, Craig E Lunte, Malcolm R Smyth.   

Abstract

Anthracyclines are chemotherapeutic drugs that are widely used in the treatment of cancers such as lung and ovarian cancers. The simultaneous determination of the anthracyclines, daunorubicin, doxorubicin and epirubicin, was achieved using CE coupled to LIF, with an excitation and emission wavelength of 488 and 560 nm, respectively. Using a borate buffer (105 mM, pH 9.0) and 30% MeOH, a stable and reproducible separation of the three anthracyclines was obtained. The method developed was shown to be capable of monitoring the therapeutic concentrations (50-50 000 ng/mL) of anthracyclines. LODs of 10 ng/mL, calculated at an S/N = 3, were achieved. Using the CE method developed, the in vitro protein binding to plasma was measured by ultrafiltration, and from this investigation the estimated protein binding was determined to be in the range of 77-94%.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18461567      PMCID: PMC2519822          DOI: 10.1002/jssc.200700629

Source DB:  PubMed          Journal:  J Sep Sci        ISSN: 1615-9306            Impact factor:   3.645


  36 in total

1.  Sample stacking by acetonitrile-salt mixtures.

Authors:  Z K Shihabi
Journal:  J Capillary Electrophor       Date:  1995 Nov-Dec

2.  Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients.

Authors:  A Andersen; H Holte; L Slørdal
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

3.  pH and drug resistance in tumors.

Authors:  Natarajan Raghunand; Robert J. Gillies
Journal:  Drug Resist Updat       Date:  2000-02       Impact factor: 18.500

4.  Docetaxel in combination with epirubicin in metastatic breast cancer: pharmacokinetic interactions.

Authors:  M Ceruti; V Tagini; V Recalenda; S Arpicco; L Cattel; M Airoldi; C Bumma
Journal:  Farmaco       Date:  1999 Nov-Dec

Review 5.  Anthracyclines: recent developments in their separation and quantitation.

Authors:  G Zagotto; B Gatto; S Moro; C Sissi; M Palumbo
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-11-25

Review 6.  Docetaxel/anthracycline combinations for breast cancer treatment.

Authors:  Gunter von Minckwitz
Journal:  Expert Opin Pharmacother       Date:  2007-03       Impact factor: 3.889

7.  Analysis of glycopeptide antibiotics using micellar electrokinetic chromatography and borate complexation.

Authors:  Carmelle Lucas; Joe P Foley; Eric S Ahuja
Journal:  Biomed Chromatogr       Date:  2003 Mar-Apr       Impact factor: 1.902

8.  Comparative serum protein binding of anthracycline derivatives.

Authors:  O Chassany; S Urien; P Claudepierre; G Bastian; J P Tillement
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

9.  Simultaneous determination of free and bound adriamycin, adriamycinol, adriamycinone and duanorubicin in plasma using column-switching technique and protein-coated pre-columns.

Authors:  S Emara; I Morita; K Tamura; S Razee; T Masujima; H A Mohamed; S M El-Gizawy; N A El-Rabbat
Journal:  Talanta       Date:  1994-11       Impact factor: 6.057

Review 10.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

View more
  2 in total

1.  Sensitive absorption-based wave-mixing detector for anthracycline drugs separated by capillary electrophoresis.

Authors:  Sandrine Berniolles; Hongjing Kan; William G Tong
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2010-06-23       Impact factor: 4.098

2.  An Nd3+-Sensitized Upconversion Fluorescent Sensor for Epirubicin Detection.

Authors:  Jingwen Mo; Long Shen; Qian Xu; Jiaying Zeng; Jingjie Sha; Tao Hu; Kedong Bi; Yunfei Chen
Journal:  Nanomaterials (Basel)       Date:  2019-11-28       Impact factor: 5.076

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.